- Detailed report to come : Phagoburn outcomes will be presented in a report to be added soon on this website.
Phagoburn is a project funded by the European Union under the 7th Framework Programme for Research and Development. Phagoburn was launched on June 1st, 2013, for 36 months.
Resistant infection is currently the main issue in burn patients
Sepsis is a major problem of large burn patients and their predominant cause of death. In high-income countries, more than 50% of the mortality rate of burn trauma is related to infection. The burn wound pathology, combined to a global intensive use of antibiotics (ATB), put patients at high risk of suffering from multidrug resistant (MDR) infections, notably carried out by the Gram-negative bacteria species: Pseudomonas aeruginosa or Escherichia coli.
In this context, the last Gram- ATB is more than 20 years old and impeded by spread out exponential resistance. New ATB with genuine mode of action to target current resistant types are out of scope. In this context, MDR Gram- infections are becoming orphan pathologies without treatment.
Fighting MDR in burn trauma is becoming an urgent medical need through innovation.
Phage therapy and Phagoburn: a promising alternative to antibiotics
Phagoburn is focused on a highly promising alternative to ATB: phage therapy. As a reminder, bacteriophages are viruses that specifically infect and kill bacteria during their replicative cycle (for more information, please see About Phage Therapy).
The main objective of Phagoburn is to assess the safety, effectiveness and pharmacodynamics of two therapeutic phage cocktails to treat either E. coli or P. aeruginosa burn wound infections.
To reach that goal, a combined Phase I/II multicentric clinical trial is currently running in 3 European countries (France, Belgium, Switzerland), by different hospital burn units.
Prior to that, a GMP (Good Manufacturing Practices) bioproduction process was implemented to produce both drug products according to current EMA (European Medicine Agency) standards. Meanwhile, the production process and the trial results will provide basis for an optimisation of current regulatory guidelines.
The Phagoburn project involves actors from France, Belgium and Switzerland. For more details, click on the following links: